7th Global Summit October 05-07, 2015 on Cancer Therapy Dubai, UAE CD49d and CD26 are independent prognostic markers for disease progression in patients.

Slides:

Advertisements

Similar presentations

Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Advertisements

Making Sense of Novel Prognostics: NOTCH1, SF3B1 Jennifer R Brown, MD PhD Director, CLL Center Dana-Farber Cancer Institute October 24, 2014.

A. a). d). c). f). b).e). g). Figure S1. NAT2 expression in lymphocytes and monocytes from a healthy volunteer. PBMC from a healthy volunteer were simple.

Immune therapy in NSCLC Presentation – 劉惠文 Supervisor – 劉俊煌教授.

Follicular lymphoma Optimal primary therapy and consolidation ? Seminars in Hematological Oncology * Israel, April M. Dreyling, Dept. of Medicine.

Goede V et al. Proc ASCO 2013;Abstract 7004.

Sino-Danish Breast Cancer Research Centre Beijing Genomic Institute, Shenzhen University of Copenhagen University of Århus University of Southern Denmark.

PROGNOSTIC SIGNIFICANCE OF PRIMARY TUMORAL FDG UPTAKE MEASURED BY PET: Systematic Review and Meta-analysis Ben A. Dwamena, MD.

Discordance in Hormone Receptor and HER2 Status in Breast Cancer during Tumor Progression Lindstrom LS et al. Proc SABCS 2010;Abstract S3-5.

Chronic Lymphocytic Leukemia. Definition Clonal B cell malignancy. Progressive accumulation of long lived mature lymphocytes. Increase in anti-apoptotic.

Agne Paner, MD Assistant professor of Medicine RUSH University Medical Center.

Flow Cytometric Abnormalities in Myelodysplastic Syndrome Raida Oudat,MD Consultant Hematopathologist at Princess Iman Research and Laboratory Sciences.

Introducing Apceden™.

IN THE NAME OF GOD By: Dr malek. References Am J Clin Pathol. 2008;130(5): © 2008 American Society for Clinical Pathology Bryant J, Picot J,

Surrogate Endpoints and Correlative Outcomes Hem/Onc Journal Club January 9, 2009.

Advanced Cancer Topics Journal Review 4/16/2009 AD.

Dr. Ziad W Jaradat Cancer Stem Cells. Recently biologically distinct and relatively rare populations of tumor-initiating cells have been identified in.

Annual prostate cancer symposium February 23, 2013 The Kimmel Cancer Center, Philadelphia, PA 2nd “ Novel Therapeutic Strategies for Prostate Cancer ”

MANAGEMENT OF MANTLE CELL LYMPHOMA IN TUNISIA R BEN LAKHAL, L KAMMOUN, K ZAHRA, S KEFI Sousse 25 MAY 2012.

Insert Program or Hospital Logo Introduction Melanoma is notoriously resistant to chemotherapy. While surgical resection and adjuvant chemotherapy can.

Postoperative Radiotherapy for Patients with Stage II or III Nonsmall Cell Lung Cancer treated with Sublobar Resections: A SEER Registry Analysis Scott.

INCREASED EXPRESSION OF PROTEIN KINASE CK2  SUBUNIT IN HUMAN GASTRIC CARCINOMA Kai-Yuan Lin 1 and Yih-Huei Uen 1,2,3 1 Department of Medical Research,

Comparison of Chronic Lymphocytic Leukemia patients expressing high or low level of ZAP70 mRNA: new prognostic factors, differences in microRNA expression.

Ibrutinib in Combination with Bendamustine and Rituximab Is Active and Tolerable in Patients with Relapsed/Refractory CLL/SLL: Final Results of a Phase.

Using Predictive Classifiers in the Design of Phase III Clinical Trials Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute.

Prognostic and Predictive Factors: Current Evidence for Individualized Therapy Predictive Molecular Markers: Hormone Receptor Status Presented by Kathleen.

Bertrand Coiffier Professor, Department of Haematology, Hospices Civils de Lyon and University Claude Bernard, Lyon, France Prior posts at the Edouard-Herriot.

European Patients’ Academy on Therapeutic Innovation Ethical and practical challenges of organising clinical trials in small populations.

Introduction Patients and Methods Results Conclusion Table 1. Baseline characteristics of the 108 patients included in the biomarker analysis. Objectives.

Phase II Trial of R-CHOP plus Bortezomib Induction Therapy Followed by Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601.

Introduction: The clinical features of neoplasia are due to capacity of tumor cells to proliferate. Neoplastic cells often have an abnormal DNA content.

Identification of localized rectal cancer (RC) patients (pts) who may NOT require preoperative (preop) chemoradiation (CRT). D. Roda 1, M. Frasson 2, E.

1 Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma:a retrospective study Hilmi Ege, Morie A.Gertz,

Population-based study on the impact of familial form of Waldenström’s macroglobulinemia on overall survival Vilhjálmur Steingrímsson1, Sigrún Helga.

Geisler C et al. Proc ASH 2011;Abstract 290.

Prognostic Implications of Neutrophil to Lymphocyte Ratio in the Treatment of Metastatic Renal Cell Carcinoma with Pazopanib and Sunitinib Ajay Raghunath1,

Big Data Analyses: The Cancer Moonshot

MicroRNA-34a: a key regulator in the hallmarks of renal cell carcinoma

Immunoscore Prognostic in Colon Cancer

The Value of Measurement of Circulating Tumor Cells in Hepatocellular Carcinoma Nashwa Sheble, Gehan Hamdy, Moones A Obada, Gamal Y Abouria, Fatma Khalaf.

Presented By Michael Lee at 2016 ASCO Annual Meeting

TBCRC (the translational breast cancer research consortium) 005 Prospective study

JONCKHEERE, Stijn 1; STEUR, Elise 1; BILLIET, Johan 1

Chronic immune activation in HIV associated Non Hodgkin lymphoma and the effect of antiretroviral therapy Brian Flepisi University of the Western Cape.

Sarah Leary, MD MS CBTTC 5/25/2016

EMT inducing transcription factor SIP1: a predictive biomarker of colorectal cancer survival and recurrence? A Patel, R Sreekumar, R Bhome, KA Moutasim,

The Diagnostic and prognostic value of CD38 and CD49d expressions in chronic lymphocytic leukemia Olfat M. Hendy, Mona A. El Shafie , Maha M. Allam.

Goede V et al. Proc ASH 2014;Abstract 3327.

Image 1 Detection of minimal residual disease (MRD) in consecutive bone marrow (BM) samples from a patient with relapse (A) and a patient still in remission.

Supporting Information for Meta-analysis

PUBLISH ONLY Journal of Thoracic Oncology

Chemotherapy and Cancer Stem Cells

Exploring Early Combination Therapy in PAH

Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system by.

Reviewer: Dr. Sunil Verma Date posted: December 12th, 2011

Transcriptional Signature of Histone Deacetylases in Breast cancer

Residual Cancer Lymphocytes in Patients With Chronic Lymphocytic Leukemia After Therapy Show Increased Expression of Surface Antigen CD52 Detected Using.

Methods to Improve Adoptive T-Cell Therapy for Melanoma: IFN-γ Enhances Anticancer Responses of Cell Products for Infusion Marco Donia, Morten Hansen,

Anti-integrin therapy in inflammatory bowel disease

Patients who have received chemotherapy (n=60)

Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy by Sara Mastaglio, Eric Wong, Travis.

PUBLISH ONLY Journal of Thoracic Oncology

Presented by: Dr.Naser Shagerdi Esmaeli

Residual Cancer Lymphocytes in Patients With Chronic Lymphocytic Leukemia After Therapy Show Increased Expression of Surface Antigen CD52 Detected Using.

Complementary Art Interventions for Children Coping with Cancer:

MRD Analysis in Chronic Lymphocytic Leukemia

Surgical resection of metachronous liver metastases

The Role of TIPE2 Protein in Invasive Breast Carcinoma

Overexpression of SUFU and GLI1 in the poor clinical outcome subgroup was confirmed by real-time PCR along with its association with disease progression.

DO NOT POST #4054 Gene expression Difference (GED) Revealed Immune Function Gene UP- or Down-regulation as Tumor-associated Inflammatory Cell (TAIC) Infiltration.

Presentation transcript:

7th Global Summit October 05-07, 2015 on Cancer Therapy Dubai, UAE CD49d and CD26 are independent prognostic markers for disease progression in patients with chronic lymphocytic leukemia Lamia Ibrahim Associate professor of clinical pathology and hematology Hematology Unit. Mansoura Cancer Institute, Mansoura Faculty of Medicine, Mansoura, Egypt

CLL is characterized by extremely variable clinical course. Several prognostic factors can predict disease progression and therapeutic outcomes in those patients. CD49d, an adhesion molecule belonging to integrin family, plays a critical role in leukocyte trafficking, activation, and survival. 7th Global Summit October 05-07, 2015 on Cancer Therapy Dubai, UAE

CD49d expression may affect prognostic stratification and overall survival in CLL patients. However, little is published on the value of CD49d as an independent prognostic factor for OS and disease progression. CD26 is a multifunctional type II cell surface glycoprotein that is widely expressed by T lymphocytes, natural killer cells. CD26 expression is very low in B- cells; however, it is up regulated following in vitro activation. 7th Global Summit October 05-07, 2015 on Cancer Therapy Dubai, UAE

The aim of this study was to evaluate the use of CD49d and CD26 as independent prognostic markers in CLL patients. We evaluated the prognostic role of CD49d and CD26 to predict the risk of lymphocyte doubling, disease progression and overall survival. 7th Global Summit October 05-07, 2015 on Cancer Therapy Dubai, UAE

Methods: The present study measured surface expression of CD49d and CD26 by three-color flowcytometry in a series of 103 previously untreated CLL patients. 7th Global Summit October 05-07, 2015 on Cancer Therapy Dubai, UAE

Results: We confirmed that CD49d and CD26 were significant predictors of lymphocyte doubling and disease progression (P < 0.001) but insignificant for overall survival (P = and respectively). Furthermore, multivariate analysis between clinical parameters and flowcytometry markers revealed that CD49d and CD26 are independent prognostic markers for lymphocyte doubling and progression to a more advanced stage. Also, concordant expression of both markers was found to improve their predictive power. 7th Global Summit October 05-07, 2015 on Cancer Therapy Dubai, UAE

Measurement of CD49d expression in CLL patients may have therapeutic implications. Anti- CD49d antibodies could impair migration and adhesion of leukaemic cells and overcome apoptotic resistance. Natalizumab, commercially available anti-CD49d antibodies, use in combination with established chemotherapy or immunotherapy protocols may give a promise in CLL therapy. 7th Global Summit October 05-07, 2015 on Cancer Therapy Dubai, UAE

Figure : the gating strategy used to quantify the expression of CD 26 by CLL cells. Histogram shows CD 26 expression after CLL cells (R1) gating. CLL cells were plotted, and the cells in the upper left quadrant were quantified as CLL cells with a high level of CD 26. 7th Global Summit October 05-07, 2015 on Cancer Therapy Dubai, UAE

Discussion: Many studies reported that CD49d and CD26 combined analysis was found to improve their power to predict the risk of lymphocyte doubling and disease progression. 7th Global Summit October 05-07, 2015 on Cancer Therapy Dubai, UAE

Conclusion: CD49d and CD26 have independent prognostic value and we suggest its use as a part of routine panel for prognostic stratification of CLL at diagnosis. 7th Global Summit October 05-07, 2015 on Cancer Therapy Dubai, UAE

THANK YOU 7th Global Summit October 05-07, 2015 on Cancer Therapy Dubai, UAE